Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B L Smiley
K Stuart

Showing results (461-470 of 476) with videos related to

Pageof 48
Sort By:
British Journal of Haematology|November 19, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaRobert K Stuart, Larry D Cripe, Michael B Maris, et al.
The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasmsBeata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
Nature|March 20, 2009
Histone modifications at human enhancers reflect global cell-type-specific gene expressionNathaniel D Heintzman, Gary C Hon, R David Hawkins, et al.
JCO Oncology Practice|October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic LeukemiaAnand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Haematologica|May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 48

Showing results (461-470 of 476) with videos related to

Sort By:
Pageof 48
British Journal of Haematology|November 19, 2014
REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemiaRobert K Stuart, Larry D Cripe, Michael B Maris, et al.
The Lancet. Haematology|June 25, 2021
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trialJeffrey E Lancet, Geoffrey L Uy, Laura F Newell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 31, 2011
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasmsBeata Holkova, E Brent Perkins, Viswanathan Ramakrishnan, et al.
Blood|January 1, 2015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutationsR Coleman Lindsley, Brenton G Mar, Emanuele Mazzola, et al.
Blood Advances|July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)Alison R Walker, Guido Marcucci, Jun Yin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2018
CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJeffrey E Lancet, Geoffrey L Uy, Jorge E Cortes, et al.
Nature|March 20, 2009
Histone modifications at human enhancers reflect global cell-type-specific gene expressionNathaniel D Heintzman, Gary C Hon, R David Hawkins, et al.
JCO Oncology Practice|October 30, 2020
Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic LeukemiaAnand P Jillella, Martha L Arellano, Manila Gaddh, et al.
Haematologica|May 26, 2018
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemiaFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Pageof 48